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Abstract
Background: The possibility to combine Low Intensity UltraSound (LIUS) and Nanoparticles (NP) could represent a
promising strategy for drugs delivery in tumors difficult to treat overcoming resistance to therapies. On one side
the NP can carry drugs that specifically target the tumors on the other the LIUS can facilitate and direct the delivery
to the tumor cells. In this study, we investigated whether Very Low Intensity UltraSound (VLIUS), at intensities lower
than 120 mW/cm2, might constitute a novel strategy to improve delivery to tumor cells. Thus, in order to verify the
efficacy of this novel modality in terms of increase selective uptake in tumoral cells and translate speedily in clinical
practice, we investigated VLIUS in three different in vitro experimental tumor models and normal cells adopting
three different therapeutic strategies.
Methods: VLIUS at different intensities and exposure time were applied to tumor and normal cells to evaluate the
efficiency in uptake of labeled human ferritin (HFt)-based NP, the delivery of NP complexed Firefly luciferase
reported gene (lipoplex-LUC), and the tumor-killing of chemotherapeutic agent.
Results: Specifically, we found that specific VLIUS intensity (120 mW/cm2) increases tumor cell uptake of HFt-based
NPs at specific concentration (0.5 mg/ml). Similarly, VLIUS treatments increase significantly tumor cells delivery of
lipoplex-LUC cargos. Furthermore, of interest, VLIUS increases tumor killing of chemotherapy drug trabectedin in a
time dependent fashion. Noteworthy, VLIUS treatments are well tolerated in normal cells with not significant effects
on cell survival, NPs delivery and drug-induced toxicity, suggesting a tumor specific fashion.
Conclusions: Our data shed novel lights on the potential application of VLIUS for the design and development of
novel therapeutic strategies aiming to efficiently deliver NP loaded cargos or anticancer drugs into more aggressive
and unresponsive tumors niche.
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Background
Cancer is a leading cause of death worldwide [1]. Tumor
heterogeneity is the main cause of resistance to thera-
peutic treatments due to the selection of surviving cancer
cells that, becoming resistant to therapies and dominant
in the tumor, are potentially responsible for recurrence
[2]. Surgical resection is the mainstay of treatment for lo-
calized disease, while combined treatments may change
the natural history of more aggressive tumors. Unfortu-
nately, few therapeutic options are available for aggressive
local or metastatic diseases (sarcoma/liposarcoma or
colon cancer) which are generally associated with a poor
prognosis. Benefits of adjuvant and neoadjuvant chemo-
therapy in advanced disease are still debated due to poten-
tial toxic side effects on normal tissues [3] and diverse
sensitivity and response to chemotherapy with the tumor
subtypes [4] potentially leading to death of many patients.
Accordingly, the identification of adequate and innovative
treatments to moderate toxic side effects occurrence,
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improve therapy efficiency and ameliorate quality of life
and life expectancy in cancer patients is demanding.
In this context, focused ultrasound (US) represents a
non-invasive technology that can be adopted for local
tumor ablation deep inside the body without causing se-
vere harm to overlying skin and adjacent normal tissues.
Of interest, during the last years, low to medium inten-
sity US was revealed as compelling tool for the improve-
ment of several emerging therapeutic applications [5–8].
Indeed, the capability of pulsed US in transferring mech-
anical energy through the different layers of the skin and
underlying tissues, generating temporary non-lethal por-
osity in cell membrane, known as sonoporation [9], en-
hances cellular membrane permeability constituting an
intriguing and novel therapeutic option for more effi-
cient strategies for gene and/or drug delivery [10].
Nanoparticles (NPs) constitute a novel not hazardous
non-viral vehicle, for the delivery, by encapsulation, of
nucleic acid (DNA, siRNA) and/or therapeutic com-
pounds that may otherwise cause systemic toxicity if de-
livered in free form. Various types of NPs have been
intensively investigated for increasing local tumor deliv-
ery [11–14]. In particular, protein-cage molecules based
on ferritins (Fts) are attracting growing interest in the
field of drug-delivery, due to their exceptional character-
istics, namely biodegradability, solubility, functionaliza-
tion versatility and remarkable capacity to bind different
types of drugs [15]. Nevertheless, albeit the outstanding
potentiality, the identification of strategies aimed to im-
prove uptake and delivery of therapeutic NPs in the
tumor site are still highly desired.
Of interest, low-intensity US (LIUS) have been shown to
enhance the delivering of liposomal drug carriers in cancer
cell increasing their therapeutic efficacy [16]. To date a
widely accepted definition of LIUS is missing, and most of
the studies in cancer cells have been generally performed
with intensity lower than 5.0W/cm2, corresponding to a
root-mean-square pressure amplitude of about 0.3MPa
[17]. Very low intensity of non-cavitational US (VLIUS) has
been reported to allow the internalization of small drugs
model molecules when higher time of exposure are used in
NIH murine fibroblast-like culture (NIH-3 T3) [18].
In this study, we investigated whether VLIUS at inten-
sities, to induce sonoporation at subcavitational levels,
lower (0.04, 0.08 0.12W/cm2) than that already reported
[19–21] could constitute a novel approach to improve de-
livery of therapeutic compounds in tumors of different type
(sarcoma and colon). At the best of our knowledge, no in-
ternalization studies have been performed using a low in-
tensity megasonic field. Accordingly, in order to verify the
efficacy of this novel modality in terms of increase selective
uptake in tumoral cells and translate speedily in clinical
practice, we investigated VLIUS in three different in vitro
experimental tumor models and normal cells adopting
three different therapeutic strategies. We demonstrated that
VLIUS enhances delivery of NPs and chemotherapy drug
in cancer cells at the experimental conditions adopted with-
out significant effects in normal cells.
Methods
Cell lines
The human lines colon adenocarcinoma (HT29), colorec-
tal carcinoma (HCT116), human fibroblast (HF), endothe-
lial umbilical vein (E926), and sarcoma (SW872 and
SW982, provided by ATCC) were all cultured in DMEM
(Dulbecco’s modified Eagle’s medium, Eurobio, Les Ulis,
France), supplemented with 10% heat-inactivated FBS
(Gibco, Life technologies, Milan, Italy), 1% penicillin/
streptomycin and 1% Glutammine (Gibco, Life technolo-
gies, Milan, Italy). The myxoid sarcoma lines 402–91 WT
[22] and the resistant counterpart 402–91 ET [23] were
maintained in RPMI medium supplemented with 10%
heat-inactivated FBS and 1% penicillin/streptomycin
(Gibco, Life technologies, Milan, Italy). All lines grow at
37 °C in a humidified atmosphere with 5% CO2.
Production of HFt-based NPs
Recombinant H-type human ferritin (HFt) and fluor
escein-labelled (HFt-FITC) were prepared as described
previously [24].
Production of lipoplex-LUC
Zwitterionic helper lipids dioleoylphosphatidylethanolamine
(DOPE) and dioleoylphosphocholine (DOPC) and the monova-
lent cationic lipids 1,2-dioleoyl-3-trimethylammonium-propane
(DOTAP) and (3β-[N-(N′,N′-dimethylaminoethane)-
carbamoyl])-cholesterol (DC-Chol) were purchased
from Avanti Polar Lipids (Alabaster, AL, USA) and used
without further purification. According to standard proto-
cols, lipid vesicles (DOPE, DOPC, DOTAP and DC-Chol)
were dissolved in chloroform at the desired molar ratio
(3:1:1:3) (patent number RM2012A000480). The solvent was
evaporated under vacuum for at least 24 h and obtained lipid
films hydrated with Tris-HCl (10mM, pH 7.4) to achieve the
desired final lipid concentration (1mg/mL). Lipid dispersions
were sonicated to clarity to prepare small unilamellar vesicles
(SUVs). Protamine sulfate salt (P) from salmon (MW=5.1
kDa) was purchased from Sigma-Aldrich (St. Louis,
MO, USA) and dissolved in ultrapure water (final
concentration = 1 mg/ml). For each well, negatively
charged P/DNA microspheres were prepared by mixing
1.25μg of P with 2.5μg of DNA vector pGL4.51-LUC-CMV--
Neo (weight ratio, RW=0.5, zeta potential =− 19.5 ± 2.5mV).
After 20min incubation, lipid/DNA NPs were prepared by
mixing negatively charged P/DNA microspheres with lipid
vesicles at cationic lipid/DNA charge ratio, ρ= 3. After pipet-
ting up and down a few times, lipoplex-LUC were kept at
room temperature for 15–30min before use.
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Size and zeta-potential measurements
The lipoplex-LUC were highly homogeneous (polydis-
persity index = 0.11 ± 0.02), small in size (RH = 255 ± 23
nm) and positively charged (ζP = 32.3 ± 11.2 mV). Hydro-
dynamic radius (RH) and zeta-potential (ζP) distributions
of lipid/DNA NPs were measured at 25 °C by a ZetaSizer
spectrometer (Malvern, UK) equipped with a 5 mW He
−Ne laser (wavelength λ = 632.8 nm) and a digital loga-
rithmic correlator. The normalized intensity autocorrel-
ation functions were analyzed by a dedicated software,
which allows obtaining the distribution of the diffusion
coefficient D of the particles. This coefficient is con-
verted into an effective hydrodynamic radius RH by
using the Stokes–Einstein equation RH = KBT/ (6πηD),
where KBT is the thermal energy and η the solvent vis-
cosity. RH and ζP are reported as the average ± standard
deviation (s.d.) of three independent measurements.
VLIUS setup
Treatments were performed with a homemade device
(Fig. 1) [18] consisting of a signal generator (Agilent
33220A), a signal amplifier device (Amplifier Research
25A250) combined with a sine wave oscillator together with
waterproof ultrasonic piezoresistive unfocussed transducer
(S.N. PA517, Precision Acoustics, UK, 6 cm diameter)
immersed at the bottom of a tank (30 × 30 × 30 cm) filled
with degassed Milli-Q water (18.2MΩ·cm, resistivity).
Ultrasonic transducer is engineered to be stimulated in
burst or continuous regimes under drive signal amplitude
of 10–100V, in the 1–5MHz frequency range, providing
the main therapeutic ultrasound settings. A sinusoidal sig-
nal at the frequency of 1MHz was generated and measured
by a needle hydrophone (S.N. 2090, Precision Acoustics) of
0.5mm diameter with a sensitivity of 483mV/MPa at 1
MHz, connected to an oscilloscope (Tektronix TDS
3052B). Continuous ultrasound exposures in terms of
spatial peak temporal average intensity (Ispta) equal to 40,
80, 120 and 150mW/cm2 were administered for fixed
time-points to hermetically sealed cell culture 60mm Petri
dish containing cells with 3.0ml of growth media. Plate was
positioned above the transducer at the water surface sub-
merged up to half of its thickness aligned coaxially with the
transducer, at a fixed distance Source-dish Surface Distance
(SSD) of 12 cm from the transducer as reported in Fig. 1.
The temperature of the water bath was monitored by
thermocouple system (Lutron electronic enterprise co.,
Fig. 1 Ultrasounds setup. For VLIUS exposure, a line of ultrasonic signal was generated by a piezoelectric unfocussed transducer immersed at the
bottom of a tank filled with degassed water, powered to a signal generator (Agilent 33220A) and a signal amplifier (Amplifier Research 25A250).
A sinusoidal signal at the frequency of 1 MHz was generated and measured by a needle hydrophone (S.N. 2090, Precision Acoustics) of 0.5 mm
diameter with a sensitivity of 483 mV/MPa at 1 MHz, connected to an oscilloscope (Tektronix TDS 3052B). Continuous ultrasound exposures in
terms of ‘spatial peak temporal average intensity’ (Ispta) equal to 40, 80, 120 and 150mW/cm2 were administered for 15 min on a petri dish (60
mm), submerged up to half of its thickness and aligned coaxially with the transducer, at a fixed distance (Source-dish Surface Distance (SSD) from
the transducer
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LTD.) and kept constantly at 25 °C (accuracy, ±1 °C) both
inside and outside the Petri dish.
HFt-based NPs delivery
SW872 and SW982 cells were plated at density of
2,0 × 105 cells on poly-l lysine coated slides in 60 mm
dish. The day after cells were incubated for 1 h with
HFt-based NPs plus or minus 15 min exposure to
VLIUS at different intensities (40–120 mW/cm2).
Following cells were counterstain with Hoechst
(SIGMA-Aldrich) and analyzed under Microscope
OLYMPUS BX53 for immunofluorescence dots. Each
experiment was carried-out in quadruplicate and re-
peated at least three times.
The lipoplex-LUC delivery
Either HT29, HCT116, HF, or E926 cells were plated in
60mm dishes at density of 5,0 × 104 cells/dish. The day
after cells were replenished with OPTIMEM, and ex-
posed to VLIUS at intensity 120 mW/cm2 for different
time lengths (5, 10, 15, 20 min). The lipoplex-LUC car-
gos were delivered to the cells right-before or right-after
VLIUS treatments. The day after culture media was re-
placed with regular grow media. Then, 48 h later cells
were collected, rinsed with PBS and lysed with 200 μl of
Passive Lysis Buffer (PLB; Cat.#E1941 Promega). Protein
lysates were clarified by centrifugation (12,000 RPM×
15min + 4 °C) and 30 μl of collected supernatants incu-
bated in triplicate with Luciferase Assay Reagent (Pro-
mega) before reading to GloMax® 96 Microplate
Luminometer. Values were normalized to protein con-
centration for each sample. Each experiment was
carried-out in triplicate and repeated at least three
times.
Drug treatments
Trabectedin kindly provided by PhamaMar S.A (Colmenar
Viejo, Spain) was stored at − 20 °C in DMSO at a concen-
tration of 1mM, and diluted in RPMI before treatment.
HF, E926, 402–91 WT and 402–91 ET cells were plated at
density of 1,5 × 105 cells in 60mm dish, and the day after
treated for 1 h with trabectedin at a concentration of 10 or
25 nM. During the treatment cells were also exposed 1, 5,
10 or 15min to VLIUS at different intensities of 20 or 40
or 80mW/cm2. Cell vitality was evaluated by Crystal vio-
let staining 48 h after drug removal. Each experiment was
carried-out in triplicate and repeated at least three times.
Image analysis
The database of available fluorescence images was divided
in training (one of the images at 40 and 80mW/cm2) and
investigation (the remaining) dataset. A Matlab tool was
developed to import each image and split it into three im-
ages, one for each RGB channel. Based on the histogram
and profiles carried-out on the green channel of
training dataset, a cut-off of 10 was set as threshold.
A visual inspection of green images and of each
histogram was performed based on the identified
cut-off to verify that green areas correspond to inves-
tigated cells. The Matlab function “regionprops” was
used to extract the area and the eccentricity of identi-
fied regions. The fraction of pixels over the cutoff of
10 was calculated as the ratio between the sum of
counts over the cuf-off and the original green images
and calculated for each image. The standard deviation
of the measured fractions was determined in the im-
ages for each experimental condition. The fractions
and the error bars were plotted according to each ex-
perimental setup.
Statistical analysis
Data were reported as mean and standard deviation. All
analyses were performed using one-way/two-way
ANOVA and Dunnett’s /Tukey’s multiple comparisons
post-hoc test as appropriate. Differences were consid-
ered statistically significant when P ≤ 0.05.
Results
VLIUS improves HFt-based NP cellular uptake in sarcoma
cells in vitro
In order to investigate VLIUS effects on endocytosis and
thus cellular uptake in sarcoma cells, we quantified the
subcellular localization of fluorescent dots generated by
HFt-based NPs delivery upon exposure to a VLIUS
source generated with a homemade device (Fig. 1). To
this aim, adherent cell cultures from two different sarcoma
lines (SW872, SW982) were incubated with HFt-based
NPs at three different concentrations (0.1–0.25 – 0.5
mg/ml) and thereafter exposed for 15 min to a VLIUS
source with constant 1.0 MHz frequency and increas-
ing intensities (40–80 - 120 mW/cm2). Cells which re-
ceived HFt-based NPs without VLIUS were adopted
as negative control. Right after incubations cells were
stained and analyzed at single cell level under micro-
scope to quantify fluorescence dots. Results revealed
that VLIUS exposure enhance HFt-based NPs delivery
in both tested lines (Fig. 2). The most efficient cellu-
lar uptake was achieved when the highest HFt-based
NPs concentration (0.5 mg/ml) was combined to the
maximum LIUS intensity (120 mW/cm2) (Fig. 2a, b).
Of interest, no fluorescence dots were observed in
control cells challenged with HFt-based NPs without
VLIUS (Fig. 2a). Fluorescence dots were homoge-
nously distributed in the cytosol with no nuclear
staining, and cell viability was close to 100% in all ex-
perimental settings explored (data not shown) sup-
porting the effectiveness of VLIUS in promoting NPs
delivery in tumor site.
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AB
Fig. 2 (See legend on next page.)
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VLIUS increases lipoplex-LUC delivery in colon cancer
cells in vitro
In order to assess whether VLIUS might increase trans-
fer of DNA-loaded NPs in cancer cells [25], we investi-
gated in hard-to-transfect HT29 colon cancer cells [26]
the delivery efficiency of DNA vector encoding Firefly
luciferase reporter (LUC) gene complexed with lipid
vesicles (lipoplex-LUC). Luciferase-based technology al-
lows to record the average of reporter expression in the
whole cell population. To define the most suitable
VLIUS wave, we took advantage from previously re-
ported analyses (Fig. 2) and selected the US frequency
and intensity that showed the highest HFt-based NPs
internalization (1,0 MHz frequency and 120 mW/cm2
intensities). We first investigated VLIUS by treatments
with different time-length exposure to optimize cell
permeability and hence delivery. Thus, HT29 cells were
incubated with equal amount of lipoplex-LUC cargos
and left untreated or incubated with VLIUS at estab-
lished intensity varying the exposure time (5, 10, 15, 20
min), and cell delivery efficiency evaluated 48 h later.
VLIUS at 15 min exposure time was revealed as the
most efficient to deliver lipoplex-LUC cargos in HT29
cells when compared to all other tested treatments
(Fig. 3a). Results observed with longer VLUIS exposure
time (20 min) might depend to the exit of lipoplex-LUC
cargos from the cells likely due to a protracted expos-
ure as reported [27].
We next investigated whether different schedule of
treatment might improve DNA delivery in HT29 cells,
and lipoplex-LUC cargos were added to the cells im-
mediately before or immediately after the established
VLIUS treatment (120 mV/cm2, 15 min). When com-
pared to untreated cells, VLIUS treatment increases
significantly lipoplex-LUC internalization in both
tested conditions, however, a significantly higher DNA
delivering was observed when lipoplex-LUC cargo
were added to the cells before VLIUS treatments, in
tested cancer cells (Fig. 3b). Hence, the therapeutic
strategies modelling could constitute a crucial proced-
ure to identify optimal setting for more efficient com-
pounds delivery.
VLIUS increases lipoplex-LUC delivery in cancer but not in
normal cells
In a therapeutic scenario, the specificity and selectivity
in tumor targeting with minor or insignificant effects on
surrounding normal tissues is detrimentally required to
maximize anti-tumor effects abating undesirable adverse
effects. Therefore, we investigated whether VLIUS treat-
ments might selectively improve delivery in cancer with-
out significant effects in normal cells. Accordingly,
analyses were performed with cancer (HT29, HCT116)
and normal fibroblast (HF) and endothelial umbilical
vein (E926) cells. Of interest, despite the intrinsic peculi-
arity of each line, VLIUS significantly increases DNA de-
livery in tumor HT29 and HCT116 lines without any
significant effect in normal cells (Fig. 4). The overall re-
sults are in support of a different response to VLIUS
that occur in tumor cells with respect to normal coun-
terpart providing novel promising insights for the design
of more selective anti-tumor treatments.
VLIUS increases trabectedin efficiency in myxoid sarcoma
but not in normal cells
US cavitation increases the permeability to bioactive ma-
terials by sonoporation perturbing the cell membrane
structures [10, 28, 29]. Accordingly, we asked whether
VLIUS might enhance delivery of trabectedin, a marine
alkaloid isolated from the tunicate Ecteinascidia turbi-
nata, with potent antitumor activity in a wide range of
tumors in particular liposarcoma [30–32]. To this aim,
myxoid sarcoma 402–91 WT, and trabectedin-resistant
402–91 ET lines and normal HF and E926 lines were
treated with trabectedin for 1 h at concentrations of 10
or 25 nM, and thereafter exposed or not to VLIUS for 1,
5, 10 or 15min with constant frequency (1.0MHz) and
the minimal intensity (80 mW/cm2) required to effi-
ciently guarantee the molecule delivery, since lower
tested intensities (20 and 40 mW/cm2) were ineffective
or protective (Additional file 1: Figure S1, A and B). As
previously demonstrated by us and other groups [22, 23,
33], trabectedin alone induced 50% of cell death in sensi-
tive 402–91 WT cells, which of interest reached 85%
when exposed to VLIUS for 1 and 5min (Fig. 5a).
(See figure on previous page.)
Fig. 2 VLIUS treatments increases HFt-based NPs cell uptake. a SW872 and SW982 cells were plated on poly-l lysine coated slides and the day
after incubated for 45 min in the presence of HFt-based NPs at different concentration (0.1–0.25 – 0.5 mg/ml) and following exposed 15 min to
VLIUS source with increasing intensities (40–80 – 120mW/cm2). Control cells were treated 1 h with HFt-based NPs alone. After incubations cells
were counterstained with Hoechst to highlight nuclei and analyzed for immunofluorescence dots. Fluorescence dots were quantified as fraction
of pixels over the cutoff of 10 using in the green channel of each image. Scale bar is 10 μm. b Histogram reported percentage of uptake and
error bars represent the standard deviation of the measured fractions in the images for each experimental condition. Each experiment was
carried out in quadruplicate and repeated at least three times. Significance was assessed by using two-way ANOVA and Tukey’s multiple
comparisons post-hoc test. * P < 0.05, **P < 0.001, ***P < 0.0001
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Noteworthy, the drug treatment followed by VLIUS for
15min induced a significant 20% of death in 402–91 ET
cells (Fig. 5b), suggesting that also in trabectedin-resist-
ant cells VLIUS increase drug uptake inducing cells
death (Fig. 5b), albeit not enough to completely revert
drug resistance, which might require longer VLUIS time
exposure likely due to drug resistance activated pathways
in these cells [33]. Of relevance, in normal cell counter-
parts, trabectedin at higher concentration (25 nM) com-
bined with VLIUS do not induce any significant effect
on cell survival in all experimental conditions tested
(Fig. 5c, d). These results are in accordance with those
shown Fig. 4, where tumor cells might reveal a different
behavior to VLIUS than normal cell, providing novel po-
tential features for selective tumor treatments. Overall,
our results support that small pores created by VLIUS
allow passive diffusion of small molecules, such as tra-
bectidin (761,84 g/mol) into the tumor lesion. This is in
agreement with a mechanistically expected effect for
low/high US, which the induced pore formation increase
the direct cytoplasmic uptake of drugs (whash-in).
Contrarily, longer VLIUS treatment (> 5min) concurs to
the exit of small molecules from the cytoplasm (wash-out)
as observed with high intensity US [32].
A
B
Fig. 3 US exposure enhances cellular uptake of LipoplexLUC NP complexes. a HT29 cells plated at density of 5.0 × 105 cells in 60 mm dish, were
delivered with lipoplex-LUC cargos and right after exposed to VLIUS source for the indicated times lengths. b HT29 cells plated as reported in A.
The day after cells where either delivered with lipoplex-LUC cargos and treated with VLIUS for 15 min (Lipoplex-LUC / VLIUS) or with opposite
schedule VLIUS for 15 min and then incubated lipoplex-LUC cargos (VLIUS / Lipoplex-LUC). In all treatments reported in (a and b) cells were
collected 48 h after treatments. DNA delivery efficiency was assessed by luciferase assays and values were normalized to protein content and
relative LUC activity quantified with respect to control set to 1.0. Each experiment has been repeated three times in triplicate, means and
standard deviation of representative experiments are reported. Significance was assessed by one-way ANOVA and Dunnett’s multiple
comparisons post-hoc test. *P < 0.05, **P < 0.001, ***P < 0.0001
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Discussion
VLIUS has been utilized for cancer therapy studies -
sonodynamic therapy, US mediated chemotherapy, US
mediated gene delivery and antivascular US therapy
[34]. Focused US has been used recently to target
DNA-loaded microbubbles located within tumor’s
neovasculature to facilitate release of genetic material
locally into the tumor [35, 36]. In particular, US has
been noted causing the process of sonoporation thus
producing transient pores in the cancer cell mem-
branes through which molecules are able to enter the
cell [20, 37, 38]. Of interest, successful delivery of
genetic material by using microbubbles induces apop-
tosis in cancer cells and reduces tumor growth [39,
40]. The underlying hypothesis is to deliver genetic
materials into specific tumor sites sparing the
non-targeted areas [41].
To date there is no widely accepted definition of
LIUS and intensity below the 5.0W/cm2 has been re-
cently suggested as maximum value for LUIS applica-
tion. Of note, the acoustic pressures required to
promote gene transfer using microbubbles are usually
greater than 0.3 MPa falling into a general classification
of moderate US intensities. In these studies, the
US-mediated methods for delivery of genetic material
was usually accomplished using non-viral and, in a few
studies, viral techniques [38, 42]. The non-viral tech-
niques have higher safety with respect to viral vectors
but are disadvantaged by the low delivery efficiencies
[43]. At the best of our knowledge, the combination of
VLIUS and NPs to deliver genetic material or VLIUS
and drug to locally deliver chemotherapy into tumors
has not been fully explored at power lower than 0.120
W/cm2 (i.e. 120 mW/cm2). In this regards, this study
would highlight the therapeutical potential of our novel
device to selectively enhance drug delivery in cancer
cells with respect to normal cells.
Of note, our data support that increasing the power
of very low intensity non-cavitational US increases
significantly the uptake of NPs in both SW872 and
SW982 human sarcoma cell lines, considered as rep-
resentative of less or more aggressive cancer cell
lines, respectively. In particular, increasing the inten-
sity up to 120 mW/cm2 the uptake significantly in-
creases still maintaining cells vitality without any side
effects. Of relevance, the use of an automated tool for
the detections of fluorescent dots allowed a fast and
precise data elaboration for accurately revealing NPs
uptake efficacy. Moreover, VLIUS significantly and se-
lectively increase the delivery of DNA-NPs cargo into
tumor cells but not in normal fibroblast and endothe-
lial cells. Of interest, similar tumor specific effects
were found when VLIUS were combined to trabecte-
din in myxoid sarcoma cells, thus opening original
scenarios for the development of novel therapeutic
treatments.
In addition, relatively few studies focused on biodis-
tribution of the agents and their elimination from the
body. Chemotherapeutic agent-loaded microbubbles
not destroyed by an US beam which has been local-
ized to a tumor will continue to circulate in the vas-
cular system and may be retained in a major organ
(e.g. spleen, followed by decreasing levels respectively
in the liver, lung, kidney and other tissues) [44–47].
Fig. 4 Ultrasound pre-treatment enhances significantly cellular NP-DNA complexes uptake in cancer cells but not normal cells. Cancer HT29,
HCT116 and normal HF, E926 cells were plated (5.0x105cells / dish) in 60 mm dishes, then twenty-four hours later, growth media was replaced
with OPTIMEM, delivered with liploplex-LUC complexes and thereafter ultrasounds treated for the indicated times. Cells were collected 48 h after
treatments. DNA transduction efficiency was evaluated by luciferase assays and values were normalized to protein content and relative LUC
activity quantified respect to control set to 1.0. Each experiments have been repeated three times in triplicate, means and standard deviation of
representative experiments are reported. Significance was assessed by one-way ANOVA and Dunnett’s multiple comparisons post-hoc test.
*P < 0.05, **P < 0.001, ***P < 0.0001
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Recently, it has been reported that the dense and stiff
extracellular matrix (ECM) can prevent drug delivery
into tumor tissues affecting therapeutic efficacy [48,
49], ECM remodeling and disruption of collagen
structure by pulsed-high intensity focused US has
been reported as a promising strategy to enhance the
deep penetration and tumor targeting in ECM-rich
tumor tissues [50]. This issue has still to be explored
with VLIUS, insonation of neoplasms with VLIUS is
easy to perform, the instruments are relatively
inexpensive and the bio-effects in adjacent normal tis-
sues are commonly minimal. Treatment times are
prolonged in comparison to those used in high inten-
sity focused US, and treatments can be delivered
non-invasively and repeatedly. Multigene approach
using a combination of antiangiogenic and pro-apop-
totic gene therapies is expected to achieve a synergis-
tic therapeutic response [51].
Conclusions
Our studies, by adopting three different in vitro experi-
mental tumor models and normal cells and approaching
three different therapeutic scenarios, demonstrated
VLIUS, as non-invasive and repeatable strategy, to medi-
ate efficient delivery in tumor cells sparing normal tis-
sues. Overall data shed novel lights on the potential
application of VLIUS for the design and development of
novel therapeutic strategies aiming to efficiently deliver
NP loaded cargos or anticancer drugs into more aggres-
sive and unresponsive tumors niche.
A B
C D
Fig. 5 US treatments increases trabectedin uptake in tumor but not in normal cell. a, b, c and d, respectively 402–91 WT, 402–91 ET, HF and E926
cells were plated at density of 150,000 cells in 60mm dish, and the day after treated for 1 h with trabectedin at a concentration of 10 or 25 nM.
During the treatment cells were also exposed 1, 5, 10 or 15 min to LIUS source at intensities of 80 mW/cm2. Cell vitality was evaluated by Crystal
violet assay 48 h after drug removal. Histogram reported percentage of viable cells and error bars represent the standard deviation. Significance
was assessed by one-way ANOVA and Dunnett’s multiple comparisons post-hoc test. *P < 0.05, **P < 0.001, ***P < 0.0001
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Additional file
Additional file 1: Figure S1. US treatments in 402–91 WT cells at lower
intensities did not increase trabectedin effect. 402–91 WT cells were
plated at density of 150,000 cells in 60 mm dish, and the day after
treated for 1 h with trabectedin at a concentration of 10 nM. During the
treatment cells were also exposed 1, 5, 10 or 15 min to LIUS source at
intensities of 40 or 20 mW/cm2 (A and B). Histogram reported
percentage of viable cells and error bars represent the standard
deviation. Significance was assessed by one-way ANOVA and Dunnett’s
multiple comparisons post-hoc test. *P < 0.05, **P < 0.001, ***P < 0.0001.
(JPG 99 kb)
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